OS Therapies Incorporated closed at $1.15 on Nov 4, down 0.86%, within 0.0% of its 52-week closing low. Volume of 503.3K shares was 1.13× its 20-day average (close to normal).
Split-adjusted performance: -22.8% over one month, -33.5% over six months, -38.5% over one year.
Short interest was 2.8M shares at the Oct 15 settlement, up 8.7% from the prior report (6.8% of float, 2.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | |
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | Compare |
| HOWLWerewolf Therapeutics | $1.09 | +1.87% | +67.6% | — | 17.5% | — | $53.0M | Compare |
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | Compare |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
| ANVSAnnovis Bio | $1.21 | +11.01% | −49.6% | — | — | — | $51.6M | Compare |
| IBIOiBio | $0.8000 | −2.85% | −54.8% | −100.0% | — | — | $51.4M | Compare |
No recent articles focused on OS Therapies Incorporated. 1 articles mention it in passing.
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
